Last reviewed · How we verify

NCT06917729: CardioBreath

Breathing Exercises of CardioBreath Application on Autonomic and Vascular Function in Hypertension

Not yet recruiting NA Last updated 8 April 2025
What this trial tests

NA trial testing CardioBreath in Hypertension in 66 participants. Not yet recruiting.

Timeline
1 August 2025
Primary endpoint
20 July 2027
20 September 2027

Quick facts

Lead sponsorInstituto de Cardiologia do Rio Grande do Sul
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment66
Start date1 August 2025
Primary completion20 July 2027
Estimated completion20 September 2027
Sites2 locations across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Instituto de Cardiologia do Rio Grande do Sul — full company profile →

Who can join

Adults 18 to 60, any sex, with Hypertension or Pre Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypertension is one of the greatest public health challenges, affecting more than one billion people worldwide and representing a significant financial and public health burden. It is responsible for a high number of cardiovascular events, such as heart attacks and strokes. Although pharmacological treatment is effective, non-pharmacological interventions are essential for the sustainable management of blood pressure, especially in its early stages. Respiratory exercises have shown potential in reducing blood pressure and improving cardiac vagal modulation, promoting cardiovascular health benefits. This study aims to evaluate the effectiveness of guided respiratory exercises using the CardioBreath app in improving vagal modulation and reducing arterial stiffness in adults with prehypertension or hypertension over six weeks. This is a randomized clinical trial involving adults with prehypertension or hypertension, divided into intervention and control groups. The intervention group will use CardioBreath to perform daily breathing exercises, with weekly remote monitoring. Assessments will include heart rate variability parameters, baroreflex sensitivity, pulse wave velocity, and quality of life. It is expected that the use of the app will significantly improve vagal modulation and arterial stiffness, demonstrating the potential of this intervention for the non-pharmacological management of hypertension. The use of CardioBreath may offer an accessible and effective alternative for blood pressure control, with the potential to be integrated into public health programs focused on low-cost, highly accessible interventions for the prevention and management of hypertension.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

Other Instituto de Cardiologia do Rio Grande do Sul trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06917729.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing